Upload
francis-richards
View
220
Download
0
Tags:
Embed Size (px)
Citation preview
Gastrointestinal Cancer
R. Zenhäusern
Rectal Cancer
Anatomic Location of CRC
Cecum 14 % Ascending colon 10 % Transverse colon 12 % Descending colon 7 % Sigmoid colon 25 % Rectosigmoid junct.9 %
Rectum 23 % 70%
Epidemiology
Increasing Incidence of CRC Incidence 30-40 / 100000 / year >70 y. of age 300 / 100000 / year third most common malignant
disease second most common cause of
cancer death
Epidemiology
1998: 4000 new cases in Switzerland
More than 350 women an 600 men die each year due to CRC
70% of CRC are resectable at diagnosis
Mortality has decreased
Decreasing mortality of CRC
5-year Survival
1960-70 1980-90
Colon cancer 40-45% 60%
Rectal cancer 35-40% 58%
WHO Classification of CRC
Adenocarcinoma in situ / severe dysplasia Adenocarcinoma Mucinous (colloid) adenocarcinoma (>50%
mucinous) Signet ring cell carcinoma (>50% signet ring cells) Squamous cell (epidermoid) carcinoma Adenosquamous carcinoma Small-cell (oat cell) carcinoma Medullary carcinoma Undifferentiated Carcinoma
TNM Primary Lymph-node Distant Dukesstage tumor metastasis metastasis stage
Stage 0 Tis N0 M0 A A
Stage I T1 N0 M0 A A1
T2 N0 M0 A B1
Stage II T3 N0 M0 B B2
T4 N0 M0 B B2
Stage III
A any T N1 M0 C C1/C2
B any T N2, N3 M0 C C1/C2
Stage IV any T any N M1 D D
Astler-Collermodified
Dukes stage
Clinical Staging of CRC
TisTis TT11 TT22 TT33 T T44
ExtensionExtensionto an adjacentto an adjacent
organorgan
MucosaMucosaMuscularis mucosaeMuscularis mucosae
SubmucosaSubmucosa
Muscularis propriaMuscularis propria
SubserosaSubserosa
SerosaSerosa
TNM Classification
Stage and Prognosis
Stage 5-year Survival (%)
0,1 Tis,T1;No;Mo > 90I T2;No;Mo 80-85II T3-4;No;Mo 70-75
III T2;N1-3;Mo 70-75III T3;N1-3;Mo 50-65
III T4;N1-2;Mo 25-45IV M1 <3
Adjuvant Chemotherapy of Colon Cancer
Therapy relapse-free Overall
5-year Survival Survival
Surgery 62 % 78 %
Surgery 71 % 83 %+ 6x 5-FU/Lv
22% reduction in death 35% reduction of recurrence
The IMPACT analysis for stages B and C disease1
5FU=370-400 mg/m2 D1 to D5 + FA 200 mg/m2 D1 to D5(every 28 days — 6 cycles) n=736
Control n=757
1.01.0
0.80.8
0.60.6
0.40.4
0.20.2
00
00 11 22 33
Stage BStage B
Stage CStage C
Time from randomization (years)Time from randomization (years)
Pro
bab
ilit
y o
f s
urv
ival
Pro
bab
ilit
y o
f s
urv
ival
Patients at riskPatients at risk
Control, Stage BControl, Stage B 423423 403403 327327 189189
Fluorouracil/folinic acid Stage BFluorouracil/folinic acid Stage B 418418 399399 328328 188188
Control, Stage CControl, Stage C 334334 298298 225225 125125
Fluorouracil/folinic acid Stage CFluorouracil/folinic acid Stage C 318318 300300 231231 161161
OverallOverallsurvivalsurvival 1.01.0
0.80.8
0.60.6
0.40.4
0.20.2
00
00 11 22 33 44
Stage BStage B
Stage CStage C
Time from randomization (years)Time from randomization (years)
Pro
bab
ilit
y o
f s
urv
ival
Pro
bab
ilit
y o
f s
urv
ival
Patients at riskPatients at risk
Control, Stage BControl, Stage B 423423 347347 256256 139139 5656
Fluorouracil/folinic acid Stage BFluorouracil/folinic acid Stage B 418418 357357 262262 140140 6060
Control, Stage CControl, Stage C 334334 223223 141141 6969 2828
Fluorouracil/folinic acid Stage CFluorouracil/folinic acid Stage C 318318 250250 179179 118118 4242
OverallOverallsurvivalsurvival
1IMPACT investigators. Lancet.1995;345:939-944.
Adjuvant chemotherapy of colon cancer
Purpose of Radio(chemo)therapy in
Rectal Cancer
To lower local failure rates and improve survival in resectable cancers
to allow surgery in primarly inextirpable
cancers to facilitate a sphincter-preserving procedure
to cure patients without surgery: very small
cancer or very high surgical risk
Rectal Cancer
Surgery is the mainstay of treatment of RC After surgical resection, local failure is
common Local recurrence after conventional surgery:
15%-45% (average of 28%)
Radiotherapy significantly reduces the number of local recurrences
Radiotherapy in the management of RC
In at least 28 randomised trials the value of either preoperative or postoperative RT has been tested
Preoperative RT (30+Gy): 57% relative reduction of local failure
Postoperative RT (35+Gy): 33% relative reduction
Colorectal Cancer Collaborative Group. Lancet 2001;358:1291
Gamma C. JAMA 2000;284:1008
Adjuvant Therapy of Rectal Cancer
1990 US NIH Consensus Conference
Postoperative chemoradiotherapy = standard of care for RC Stage II,II
The consensus statement was based upon the results of three randomised trials
Postoperative radiochemotherapy
GITSG NCCTGNSABP-R01
Number of pts. 202 204 555
Surgery alone LF (%) 24 25S (%) 43 43
Radiotherapy LF (%) 20 25 16S (%) 52 47 41
Chemotherapy LF (%) 27 21S (%) 21 53
Chemoradioth. LF (%) 11 14 8S (%) 59 58
ESMO Recommendations
Resectable cases Surgical procedure: TME Preoperative RT: recommended Postoperative chemoradiotherapy: T3,4
or N+
Non-resectable cases: local recurrences Preoperative RT with or without CT
Optimal combination of chemo- radiotherapy?
If radiochemotherapy is used postoperatively, protacted infusion of 5-FU is superior to bolus 5-FU during radiotherapy
O`Connell. NEJM 1994;331:331
Protacted Infusion of 5-FU
660 patients with stage II,III rectal cancer
PI-FU Bo-FU
Local recurrence ns ns p=0.11
4-year DFS 63% 53% p=0.01
4-year OS 70% 60%p=0.005
O`Connell. NEJM 1994;331:331
Preoperative RT in resectable RC
Swedish Rectal Cancer Trial
1168 patients randomised to 25 Gy (5x5) PRT or no RT
Surgery alone Preop. RT
Rate of local recurrence27% 11% p<0.001
5-year overall survival 48% 58% p=0.004
Swedish Rectal Cancer Trial. NEJM
1997;336:980
Predicting risk of recurrence in RC
Surgery-related
-Low anterior resection
-Excision of the
mesorectum
-Extend of
lymphadenectomy
-postoperative anastomoticleakage
-Tumor perforation
Tumor-related
-Anatomic location
-Histologic type
-Tumor grade
-Pathologic stage
-radial resection margin
-neural, venous, lymphatic invasion
Incidence of local failure in RC
T1-2,No,Mo <10% T3,No,Mo 15-35% T1,N1,Mo 15-35% T3-4,N1-2,Mo 45-65%
Total Mesorectal Excision (TME)
Local recurrence rates after surgical resection of RC have decreased from about 30% to < 10%
1. Radio(chemo)therapy 2. Importance of circumferential margin
(TME)
Total Mesorectal Excision (TME)
TME series with local recurrence rates of 5% Other series report recurrence rates of 5-15% Inclusion of patients with T1-2,No disease Experience of the surgeon is important Higher complication rates
TME will not remove all tumor cells in the pelvis in all patients, RT may eradicate th remaining ones
TME +/- preoperative RT
Dutch Colorectal Cancer Group 1861 patients randomised TME vs PRT+TME
TMEPRT+TME
Recurrence rate 2.4% 8.2% OS ns ns
Kapiteijn E. NEJM 2001;345:638
Preoperative therapy for sphincter preservation
Phase II data with no randomised trials Optimal regimen not known Long-term functional outcome? Five of seven trials report sphincter
preservation in approximately 75%
Preoperative Therapy in locally advanced/non-resectable rectal
cancer
Favourable treatment results in phase II trials with preoperative radiochemotherapy
Chemoradiotherapy was viewed as standard based on phase II data
Preoperative vs. Postoperative chemoradiotherapy for rectal
cancer
Randomized trial of the German Rectal Cancer study Group: Sauer R et al. N Engl J Med 2004;351:1731-40
cT3 or cT4 or node-positive rectal cancer
50,4 Gy (1.8 Gy per day)
5-FU: 1000 mg/m2 per day (d1-5) during 1. and 5. week
Preoperative vs. Postoperative chemoradiotherapy for rectal
cancer
Preop CRTPostop CRT
Patients N=415 N=384 5 y. OS 76% 74% p=0.8 5 y. local relapse 6% 13% p=0.006 G3,4 toxic effects 27% 40% p=0.001
Increase in sphincter-preserving surger<y with preop Th.
Sauer R et al. N Engl J Med 2004;351:1731-40
Capecitabine in combination with preoperative radiotherapy
Phase I/II studies demonstrate that capecitabine is effective and well tolerated in combination with preoperative radiotherapy
Capecitabine 825 mg/m2 twice daily given continously with standard RT can be recommended
Phase II trials are ongoing PETACC-6: capecitabine + RT vs. Capecitabine
+Oxalipaltin +RT
R. Glynne-Jones. Annals of Oncology 2006;17:361-371
Capecitabine in combination with preoperative radiotherapy
Phase II study in locally advanced rectal cancer 53 pat. with T3, N0-2, T4, N0-2 cancer Capecitabine 825 mg/m2 twice daily for 7 days/week
and concomitant RT (50.4 Gy/28 fractions) Overall response: 58% Downstaging rate: 57% Pathological CR: 24% Sphincter-saving Op: 59% (20/34 pat. <5cm )
A.De Paoli et al. Annals of Oncology 2006;17:246-251
Chemotherapy with preoperative radiotherapy in
rectal cancer
Adding fluorouracil-based chemotherapy to preoperative or postoperative RT has no significant influence on survival.
Chemotherapy before or after surgery, confers a significant benefit with respect to local control.
Bosset JF et al. N Engl J Med 2006;355:1114-1123
Esophageal Cancer
Esophageal Cancer
Lifetime risk: 0.8% for men, 0.3% for women
Mean age at diagnosis 67 years Sixth leading cause of death from cancer Overall incidence: 5 /100000 persons Relative incidence of squamous-cell to
adenocarcinoma decreased from 2:1 (1988) to 1.2:1 (1994)
Surgery for Esophageal cancer
Five-year survival after complete surgical removal of the tumor:
Stage 0: 95% Stage I: 50-80% Stage IIA: 30-40% Stage IIB: 10-30% Stage III: 10-15%
Preoperative RT for Esophageal cancer
Five randomized trials (>100 pat.) have compared preoperative RT with immediate surgery
Total dose of RT: 20 – 40 Gy None of the studies demonstrated a
survival advantage
Arnott SJ et al. Int J Radiat Oncol Biol Phys 1998;41:579-583
Preoperative CT for Esophageal cancer
A randomized US study (N=440) showed no benefit: 3 cycles cisplatin / fluorouracil
2y survival 35% vs 37% Kelsen et al. N Engl J Med 1998;339:1979-1984
A randomized British study (N=802) suggested an increase in survival
2 y survival 43% vs 34% MRC Oesophageal Cancer Working Group. Lancet
2002;359:1727-1733
Preoperative CT and RT for Esophageal cancer
Eight randomized trials ( seven negativ, one showed a benefit)
Study N CT RT MS 3yS(mo) (%)
Le Prise 1994 41/45 C/F 20 Gy 10/10 9/17 Apinop 1994 34/35 C/F 40 Gy 7/10 20/26 Walsh 1996 55/58 C/F 40 Gy 11/16 6/32 Bosset 1997 139/143 C 37 Gy 19/19 37/39 Urba 2001 50/50 CVF 40 Gy 18/17 16/30 Burmeister 2002 128/128 C/F 35 Gy 22/19
Nonsurgical CT and RT
Cisplatin / Fluorouracil and RT (50 Gy) Long-term survival in approximately 25
% Increasing the radiation dose was
unsuccessful
Minsky BD et al. J Clin Oncol 2002;20:1167-1174
Gastric Cancer
Gastric Cancer
9.9% of all new cancer diagnosis 12% of all cancer deaths Overall 5 y. survival 15%-35% Declining incidence in the West
Surgery for Gastric Cancer
Stage I: 5y survival 58%-78% Stage II: 5y survival 34% Local or regional recurrence after
gastric resection with curative intent: 40-65%
Adjuvant chemoradiotherapy ?
CRT after surgery vs. surgery alone
Randomized trial n=556, T1-4, No-2 Resected adenocarcinoma of the stomach or
gastroesophageal junction
1 cycle leucovorin 20mg/m2, Fluorouracil 425 mg/m2 day 1-5 RT 45 Gy (1.8Gy per day), beginning on day 28
Lv 20mg/m2, FU 400 mg/m2 d. 1-4 and last 3 d. of RT 2 cycles leucovorin 20mg/m2, Fluorouracil 425 mg/m2 day 1-5
MacDonald et al. N Engl J Med 2001;345:725-730
CRT after surgery vs. surgery alone
Results: CRT Surgery
3y survival 50% 41% p=0.005
Med. OS 36 mo 27 mo3y RFS 48% 31%Local reccurence 19% 29%
MacDonald et al. N Engl J Med 2001;345:725-730
Perioperative chemotherapy vs.
surgery alone
Randomized trial: n=503 Chemotherapy:
3 preoperative and 3 postoperative cycles
Epirubicin 50mg/m2, cisplatin 60mg/m2, day1
Fluorouracil cont i.v. 200mg/m2, day 1-21
Cunningham et al. N Engl J Med 2006;355:11-20
Perioperative chemotherapy vs.
surgery alone
Results: CT Surgery
5y OS 36.3% 23% Local recurrence 14.45% 20.6%
Cunningham et al. N Engl J Med 2006;355:11-20